Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Beam Therapeutics has raised $100.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in February 2026.
Beam Therapeutics's investors include ARCH Venture Partners, Sixth Street, Redmile Group, Foresite Capital, Perceptive Advisors.
Beam Therapeutics is headquartered in Cambridge, United States.
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Beam Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Beam Therapeutics — Funding & Investors." VCBacked, February 24, 2026, https://www.vcbacked.co/company/beam-therapeutics. Accessed July 20, 2026.
VCBacked. (2026). Beam Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/beam-therapeutics
{{cite web |title=Beam Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/beam-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated